NCT07547592: Gemcitabine Docetaxel Phase 2 Trial for Soft Tissue Sarcoma
Summary
The NIH registered a Phase 2 clinical trial (NCT07547592) evaluating gemcitabine and docetaxel with or without bevacizumab (Onbevzi) in patients with neoplasms of connective and soft tissue at unspecified anatomical sites. The trial includes two arms: Arm 1 adds bevacizumab at 15 mg/kg on Day 1 of each 21-day cycle, while Arm 2 uses gemcitabine and docetaxel alone on the same schedule. Both arms administer gemcitabine and docetaxel as 60-minute intravenous infusions on Day 8.
“Arm2- On Day 1 of each 21-day cycle, gemcitabine will be administered first, followed by docetaxel as an intravenous infusion.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
The NIH added a new Phase 2 clinical trial registration (NCT07547592) to ClinicalTrials.gov describing a two-arm study in patients with soft tissue sarcoma. Arm 1 combines bevacizumab (Onbevzi) at 15 mg/kg with gemcitabine and docetaxel, while Arm 2 uses gemcitabine and docetaxel only, both on 21-day cycles with Day 8 drug administration. The trial is listed as Phase 2 with an estimated start date.
Affected parties include clinical investigators, oncology research sites, and pharmaceutical manufacturers of gemcitabine, docetaxel, and bevacizumab (Onbevzi) who may need to ensure supply chain alignment if participating. Sponsors considering competing trials in this indication should review the existing protocol to assess overlap or competitive enrollment risk.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Gemcitabine and Docetaxel With or Without Bevacizumab (Onbevzi) for Soft Tissue Sarcoma
Phase 2 NCT07547592 Kind: PHASE2 Apr 23, 2026
Abstract
Arm1- bevacizumab (Onbevzi) at a dose of 15 mg/kg administered as a 30-minute intravenous infusion on Day 1 of each 21-day cycle, followed by intravenous infusion of gemcitabine and docetaxel in sequence. On Day 8 of each cycle, gemcitabine and docetaxel will be administered as a 60-minute intravenous infusion.
Arm2- On Day 1 of each 21-day cycle, gemcitabine will be administered first, followed by docetaxel as an intravenous infusion. On Day 8, gemcitabine and docetaxel will be administered as intravenous infusions.
Conditions: Neoplasms of Connective and Soft Tissue With an Unspecified Anatomical Site
Interventions: Bev + Gem + Doc, Gem + Doc
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.